Stem Cell Transplant Quality

• KHCC holds FACT-JACIE accreditation for Hematopoietic Cellular Therapy and JCI disease-specific cancer certification; approximately 200 transplants annually with >85% success rate (2022)
• Published 5-year survival rates of 70% (2003–2009) improved to >85% (2022); day-100 treatment-related mortality of 4.8% for Hodgkin's lymphoma autologous transplant and 3% for thalassemia exceed international benchmarks
• All transplant modalities available: autologous, allogeneic (matched related/unrelated), haploidentical, and cord blood; HEPA-filtered isolation rooms and advanced cell processing laboratory (CTAG) provide specialized infrastructure
• Comprehensive international patient services: dedicated Office of International Patient Affairs with visa coordination, medical translation, financial estimation, and personal coordinator; EBMT registry participation for international outcome benchmarking
• Concentration of transplant capacity at single KHCC center (87% of national volume 2003–2017) and absence of domestic bone marrow donor registry present as programmatic gaps despite robust international registry access

Read the full Jordan report →

• Hadassah achieved full JACIE accreditation (2018); Sheba holds JACIE for HPC collection + FACT/NETCORD and AABB certifications; Schneider Children's JACIE-accredited; all major centers JCI-accredited
• Israel records world's highest allogeneic HCT rate of 441 per 10 million inhabitants and highest CAR-T rate of 231 per 10 million per EBMT 2022-2023 data
• Reported survival rates of 85-90% for leukemia at major centers; 93% overall survival for SCID patients identified via newborn screening at Sheba
• Ezer Mizion registry contains 1.28+ million donors with WMDA accreditation and NMDP affiliation providing access to 40+ million global donors; 6,544 transplants facilitated in 50 countries
• Sheba Medical Center operates as Europe's largest CAR-T center with point-of-care manufacturing in 10-11 days; Sheba holds global patient services with 8-language support and institutional recognition as 8th-ranked hospital globally by Newsweek in 2024

Read the full Israel report →

• Multiple internationally accredited centers: NCIS is the only HSCT programme in Asia with FACT accreditation; SGH holds FACT-JACIE (2016); NUH Paediatric achieved FACT (2012); Singapore Cord Blood Bank is FACT-NetCord certified; four private hospitals hold JCI accreditation
• Exceptional outcome statistics: KKH paediatric allogeneic HSCT (2019–2023) showed 1-year OS of 90.4% with 1-year TRM of 3.3%; national HSCT mortality during COVID-19 remained below 10% versus 19% internationally
• Comprehensive donor registry and modalities: BMDP links to 30+ million donors through 90+ WMDA registries; all transplant types available including haploidentical (Haplo-2017 protocol) and cord blood; SGH performs 80–100 transplants annually
• Established international patient infrastructure: JCI-accredited private hospitals provide airport transfer, language interpretation, visa assistance, accommodation arrangement; NCIS maintains dedicated international patient pathway; CFCH operates with transparent cost structures
• Published outcomes and international benchmarking: Singapore is APBMT registry member, hosted 29th APBMT Congress 2024; outcomes published in peer-reviewed journals and compared to international benchmarks; SGH explicitly states outcomes comparable to major global centres

Read the full Singapore report →

• University of Debrecen Division of Haematology holds JACIE accreditation; MEDYAG Kft. (Debrecen) received JACIE accreditation in 2024
• 5-year overall survival of 86% for autologous SCT in Hodgkin lymphoma (n=126, 2016–2020 multicenter study) and 71.4% two-year OS for pediatric AML, exceeding Score 4 survival thresholds
• Documented annual transplant volume of 101 procedures at Debrecen in 2017 with target capacity of 150/year post-expansion; national volume approximately 400 procedures annually
• WMDA member since 1992 with EMDIS-connected online access to approximately 40 million international donors; all five transplant modalities available including haploidentical and cord blood programs
• International patient services established at major centers (Semmelweis International Patient Office, Debrecen coordination, Déméter House with 14 family apartments for pediatric patients), though adult-specific dedicated housing and coordinator roles are limited
• Active participation in EBMT registry for European-level benchmarking; University of Debrecen membership in EuroBloodNet for rare hematological diseases

Read the full Hungary report →

• Over 250 annual transplants at leading centers with 70-90% success rates for matched-related donor procedures, demonstrating high volume and strong outcomes comparable to international standards
• TURKOK registry with 600,000 WMDA-registered donors established 2015 and participation in EMDIS international network, enabling 92-day average donor search compared to 176 days for German registry
• Comprehensive international patient infrastructure with 24/7 international patient centers, all-inclusive packages (€45,000-€65,000), dedicated accommodation and translator support, plus specialized transplant modalities (autologous, allogeneic, haploidentical, CAR-T)

Read the full Turkey report →

• 267 JSTCT-certified HCT centers (189 adult, 78 pediatric) performing 5,500+ annual transplants with rigorous national certification and mandatory TRUMP registry oversight
• JMDP donor registry: 547,708 donors with 96% 8/8 HLA match probability and ~122 day search-to-transplant timeline; Japan accounts for >30% of global cord blood transplants via 11 public banks
• Five-year net survival rates: lymphoid malignancies 57.3%, cord blood 100-day survival 78.9%, with improving trends; younger patients (15-44) achieving 72.3% for myeloid malignancies
• Government-supported Visa for Medical Stay (up to 6 months renewable), interpreter services at major centers, and 25 JCI-accredited hospitals in Japan
• International collaboration: JSTCT/JDCHCT integrated with CIBMTR and EBMT for outcome benchmarking; access to novel therapies including ruxolitinib and ibrutinib with published Japanese cohort data

Read the full Japan report →

• 14+ JACIE-accredited centers achieved or renewed accreditation in 2024; Royal Marsden >200 annual transplants, King's College Hospital ~200/year, GOSH ~90-100/year
• Adult 5-year overall survival approximately 50%; paediatric 1-year allograft survival 82-94% at GOSH; high-volume centers demonstrate superior outcomes for standard-risk populations
• UK Registry 2.37 million donors; global access to 40+ million through WMDA; NHS Cord Blood Bank 20,000 units (4th largest globally); haploidentical and cord blood programs available
• GOSH Harris International Patients Centre with Dubai liaison office; established international patient services and private cost documentation (£150,000-£200,000)
• All transplant modalities available including CAR-T therapy; regular outcome reporting to EBMT international registry and BSBMTCT database

Read the full United Kingdom report →

• FACT accreditation (April 2024) — first in UAE, second in Middle East; AABB accreditation (2025); JCI Gold Seal and DoH Centre of Excellence designation
• Autologous HSCT: 97% one-year overall survival with 100% engraftment in 48 adult patients; pediatric matched related donor: 100% overall survival and 0% transplant-related mortality in 25 consecutive cases
• Individual ADSCC and Burjeel annual volumes estimated at 25-40 transplants per center (below Score 4 threshold of >50), with cumulative UAE program ~260 transplants since 2020
• Allogeneic 100-day treatment-related mortality of 33% in small early cohort (n=9), significantly above international benchmark of 10-15%
• Emirates Bone Marrow Donor Registry exists but historically small with under-representation of Arab donors; no documented average search time for unrelated donor matching
• Haploidentical transplant programs not formally documented in public literature, limiting donor options for patients without sibling matches
• No formally integrated accommodation arrangements for 3–6 month international patient stays; dedicated international coordinators present but housing must be arranged independently

Read the full United Arab Emirates report →

• 38 HSCT centers across South Korea with Seoul National University performing >3,500 cases as of 2024 and Asan Medical Center performing 3,700 combined autologous and allogeneic transplants (1993-2016)
• Treatment-related mortality rates of 2.9% at 50 days and 8.3% at 100 days, demonstrating excellent outcomes compared to international standards (Score 5 threshold: <10%)
• No FACT or JACIE accredited transplant centers identified; accreditation exists only for general hospital quality (JCI), not transplant-specific standards
• Comprehensive international patient services including multilingual staff (English, Chinese, Mongolian, Russian, Japanese, Arabic), dedicated International Healthcare Centers at major hospitals, and over 20,086 international patients annually visiting Asan Medical Center
• Access to international donor registries with 42 million potential donors globally through partnerships; domestically, 28% of Korean patients find matched donors through KMDP with additional access to Japanese registry (JMDP) for 30% of patients without domestic matches
• All major transplant modalities available including haploidentical, cord blood, and alternative donor programs; centers actively offering CAR-T cell therapy since 2022

Read the full South Korea report →

• 100-day treatment-related mortality of 1.9% for autologous and 6.1% for allogeneic HSCT—better than Score 5's <10% threshold [Outcomes of HSCT in Mexico - Leon Rodriguez et al. - 2017]
• Ten-year overall survival rates of 61% for autologous and 57% for allogeneic HSCT within 60-70% range for Score 4 [Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran - 2017]
• Approximately 118 annual transplants across four major public centers (2015-2018), exceeding 50-transplant threshold for Score 4 [Outcomes of HSCT in Mexico - Leon Rodriguez et al. - 2017]
• At least one FACT-accredited center in Monterrey, but no documented JACIE accreditation; falls short of Score 5's 'multiple' centers [FACT Accredited Institutions - 2024]
• Infrastructure for international patients 'markedly underdeveloped' with no dedicated long-term housing and no documented international patient coordinators [Research Report Analysis]
• Underdeveloped domestic bone marrow donor registry (DONORMO/UCBB); must rely on international registries like NMDP/Be The Match for unrelated donor searches [Outcomes of HSCT in Mexico - Leon Rodriguez et al. - 2017]
• Haploidentical programs established with 64.1% 60-month overall survival at Centro Médico ABC, comparable to high-income countries [Outcomes of Haploidentical SCT for ALL Mexico - Carrillo Jurado et al. - 2025]

Read the full Mexico report →

• No FACT or JACIE accreditation at any Malaysian center; only JCI (hospital-wide) accreditation at private hospitals
• 60-70% overall survival rates (2010-2015 cohort); 63% 10-year OS for AML allogeneic patients (1987-2010)
• Approximately 400 annual transplants nationally; Hospital Ampang performs ~200/year, exceeding major center thresholds
• Only 3% of allogeneic transplants use matched unrelated donors; MSCR has 31,200 donors vs. international registries with millions
• Treatment-related mortality not systematically reported or disclosed publicly
• No annual published outcome reports or international benchmarking; peer-reviewed data is historical (pre-2015)
• Dedicated International Patient Centres at JCI-accredited hospitals with multilingual coordinators and telemedicine follow-up
• 13 transplant centers with access to haploidentical, cord blood, and autologous modalities

Read the full Malaysia report →

• 2,057 total HSCTs in 2024 (1,191 autologous + 866 allogeneic) across 20 Ministry of Health-authorized centers; University Children's Hospital Krakow holds JACIE accreditation (2024) for pediatric program; no confirmed JACIE certification for major adult centers
• 3-year overall survival rates from PALG multicenter study: 73.6% (PTCy-MMUD), 49.1% (PTCy-haploidentical), 33.4% (ATG-MMUD); treatment-related mortality not publicly consolidated
• Donor registry of 2.47M Polish donors (DKMS Fundacja + Poltransplant) represents one of world's largest national pools with 92%+ HLA intermediate-to-high resolution typing; access to 44M global donors via WMDA
• All transplant modalities available: autologous, allogeneic related/unrelated, haploidentical (94 in 2024), cord blood (PBKM EBMT member), and commercial CAR-T (5 certified centers since 2022)
• International patient infrastructure underdeveloped: no nationally coordinated medical tourism pathways, no dedicated international patient coordinators at major public centers, no purpose-built accommodation for 3-6 month post-transplant stays; costs $20,000-$60,000 (60-80% below Western Europe)
• Active research culture with PALG/Polish Myeloma Group publications in peer-reviewed journals, EBMT registry participation, and Wrocław HLA proficiency testing serving 67 labs in 16 countries; no center-level outcome benchmarking published for international comparison

Read the full Poland report →

• Four FACT-JACIE Hematopoietic Cellular Therapy–accredited institutions with 3,991 annual transplants (1,462 allogeneic, 2,529 autologous)
• Autologous 2-year overall survival 82% with non-relapse mortality 8%; allogeneic 2-year overall survival 59.8% with non-relapse mortality 21.6% across 11,210 patients (2012–2023)
• REDOME donor registry is world's 3rd largest with approximately 4–5 million registered donors; haploidentical and cord blood programs available
• Hospital Israelita Albert Einstein International Patient Center with JCI accreditation, FACT-JACIE certification since 2012, and over 1,300 completed transplants; CHN Niterói performs ~130 annual transplants with 26 HEPA-filtered isolation rooms
• Regular outcome reporting to CIBMTR with outcomes explicitly described as comparable to US registry data; ANVISA regulatory oversight (RDC 214) and Ministry of Health SIPAC accreditation system in place

Read the full Brazil report →

• Four active transplant centers (Siriraj, Ramathibodi, Chulalongkorn, Pramongkutklao) with 120-150 total annual transplants (approximately 30-37 per center)
• Samitivej reports 92% one-year survival for bone marrow transplantation, exceeding European benchmarks of ≥88%
• 0% 100-day transplant-related mortality for pediatric thalassemia haploidentical transplants, compared to European benchmark of ≤4%
• No Thai centers appear in FACT or JACIE accredited databases - only JCI general hospital accreditation available
• Full access to international donor registries with over 30 million potential donors worldwide through WMDA membership
• Haploidentical programs reduce donor matching requirements to 50%, with family members serving as donors
• Comprehensive international patient services at major hospitals with multilingual support, accommodation coordination, and telemedicine follow-up
• High chronic GVHD rates noted, especially in peripheral blood stem cell transplant recipients
• No national outcome registry or systematic benchmarking against international standards

Read the full Thailand report →

• Only 1 FACT-accredited transplant center identified in Gujarat versus multiple needed for Score 5
• Survival rates of 60-90% with major hospitals reporting 90%+ success rates, comparable to international standards
• Day-100 non-relapse mortality of 18% in recent haploidentical cases, exceeding Score 4 threshold of 10-15%
• DATRI registry with 657,361 donors but only 15% of patients finding domestic matches; international registry access through partnerships
• 2,533 transplants in 2019 across 114 centers (~20-28 per center average), though major centers exceed 100+ annual volume
• Comprehensive international patient services with dedicated Guest Relation Officers, accommodation support, and 3-month follow-up programs
• Regulatory framework incomplete: recommended methods and release criteria for graft manipulation still not available in India

Read the full India report →

• No Colombian transplant center holds FACT or JACIE accreditation; Fundación Valle del Lili holds JCI and EFI laboratory accreditation but not international transplant center credentials.
• National aggregate success rate of 62% for first hematopoietic progenitor cell transplants; Fundación Valle del Lili reports 87% at 1 year and 81% at 5 years for haploidentical transplants in inborn errors of immunity.
• Infection-related mortality accounts for 45% of treatment-related deaths (versus 5–11% internationally), with 68.1% of PICU admissions post-transplant driven by infection and 55.8% of organisms showing antimicrobial resistance.
• Instituto de Cancerología Las Américas performs ~140 transplants annually; Clínica de Marly has completed 3,000+ procedures over 30+ years; limited domestic donor registry of only 4,435 HLA-typed donors with 97.4% Mestizo composition.
• Bilingual international patient coordinators, virtual pre-consultation, and remote follow-up available at major centers; cost savings of 60–70% versus US; however, no dedicated transplant housing and Level 3 US travel advisory noted.

Read the full Colombia report →